renzapride
Small moleculeexperimental
Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00268879)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
- Serotonin 3a (5-HT3a) receptorANTAGONIST
HTR3A antagonist
- Serotonin 3 (5-HT3) receptorANTAGONIST
Serotonin 3 (5-HT3) receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(N)c(Cl)cc1C(=O)NC1CCN2CCC1C2- Mol. weight
- 309.8 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRenzapride ↗
- ChEMBLCHEMBL296522 ↗
- ChEMBLCHEMBL159825 ↗
Also known as
- 4-amino-5-chloro-2-methoxy-n-(1-azabicyclo-(3.3.1)-non-4-yl)benzamide
- benzamide, 4-amino-n-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxy-, monohydrochloride, endo-(+-)-
- brl 24924
- brl-24924
- renzapride
- renzapride
- renzapride
- renzapride
- renzapride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00607971 | Phase 3 | Apr 1, 2006 | Alizyme, Harvard University |
| NCT00268879 | Phase 3 | Dec 1, 2005 | Alizyme, Harvard University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alizyme | For profit | 2 | 2 | 1 | 2005 |
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1